919 related articles for article (PubMed ID: 21646602)
21. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
22. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
23. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.
Watanabe T; Tobinai K; Shibata T; Tsukasaki K; Morishima Y; Maseki N; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Takeuchi K; Nawano S; Terauchi T; Hotta T
J Clin Oncol; 2011 Oct; 29(30):3990-8. PubMed ID: 21931035
[TBL] [Abstract][Full Text] [Related]
24. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
25. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
26. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma.
Sohn BS; Kim SM; Yoon DH; Kim S; Lee DH; Kim JH; Lee SW; Huh J; Suh C
Ann Hematol; 2012 Nov; 91(11):1731-9. PubMed ID: 22752193
[TBL] [Abstract][Full Text] [Related]
27. [Treatment outcome in primary testicular non-Hodgkin lymphoma].
Iványi JL; Marton E; Plander M; Engert ZV; Tóth C
Orv Hetil; 2013 Oct; 154(42):1666-73. PubMed ID: 24121219
[TBL] [Abstract][Full Text] [Related]
28. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
31. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
[TBL] [Abstract][Full Text] [Related]
32. Diffuse large-cell lymphoma of the testis.
Tondini C; Ferreri AJ; Siracusano L; Valagussa P; Giardini R; Rampinelli I; Bonadonna G
J Clin Oncol; 1999 Sep; 17(9):2854-8. PubMed ID: 10561362
[TBL] [Abstract][Full Text] [Related]
33. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
34. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution.
Tokiya R; Yoden E; Konishi K; Kamitani N; Hiratsuka J; Koresawa R; Hirose T; Sano F; Tokunaga H; Kondo T; Wada H; Sugihara T
Int J Hematol; 2017 Oct; 106(4):533-540. PubMed ID: 28612278
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
37. Central nervous system involvement in diffuse large B-cell lymphoma.
Yamamoto W; Tomita N; Watanabe R; Hattori Y; Nakajima Y; Hyo R; Hashimoto C; Motomura S; Ishigatsubo Y
Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301
[TBL] [Abstract][Full Text] [Related]
38. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution.
Fukuhara S; Watanabe T; Munakata W; Mori M; Maruyama D; Kim SW; Kobayashi Y; Taniguchi H; Maeshima AM; Tanosaki R; Matsuno Y; Tobinai K
Eur J Haematol; 2011 Nov; 87(5):434-40. PubMed ID: 21740461
[TBL] [Abstract][Full Text] [Related]
39. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Schmitz N; Zeynalova S; Glass B; Kaiser U; Cavallin-Stahl E; Wolf M; Haenel M; Loeffler M; Truemper L; Pfreundschuh M
Ann Oncol; 2012 May; 23(5):1267-1273. PubMed ID: 21989328
[TBL] [Abstract][Full Text] [Related]
40. Pilot trial of systemic methotrexate plus R-CHOP regimen with intrathecal methotrexate for simultaneous central nervous system and systemic diffuse large B cell lymphoma.
Yoo KH; Lee JY; Lim SH; Ko YH; Kim SJ; Kim WS
Acta Haematol; 2015; 133(2):179-82. PubMed ID: 25323539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
